JAK inhibitors: promising treatment for people with severe COVID-19 illness. But will they be affordable for all?

More than 18 months into the pandemic, there are still very few therapeutic options for COVID-19 patients. By Leena Menghaney, Global IP Advisor, MSF Access Campaign and Julien Potet, MSF Access Campaign Policy Advisor, NTDs and Vaccines.